The impending flood of filing Actos lawsuits already began. The manufacturer of the world’s best selling anti-diabetic drug is now in front of hundreds of lawsuits because of the recent concern about the increased risk of developing bladder cancer connected with the long-term use of their diabetes medication Actos (Pioglitazone), according to a recent report of Associated Press.
The filing of lawsuits in United States began just weeks after the FDA announcement issued in June 2011 concerning Actos bladder cancer risk. According to a recent report, more than 25 Actos bladder cancer lawsuits have already filed against the manufacturer (Takeda Pharmaceuticals) in different federal district courts so far this September. Moreover, according the requests from the Actos bladder cancer affected patients, personal injury lawyers are now predicting thousands of lawsuits may be filed before the end of the year.
The first Actos bladder cancer lawsuit was filed on behalf of a woman named Nancy Rios, a 54-year-old hospital secretary who filed her lawsuit due to her recurrent bladder cancer for Actos use. She was using the drug for nearly a decade. She was first diagnosed with bladder cancer in 2009, and had her second operation to remove bladder tumors in this June, according to a recent report of Associated Press. In addition, she was worried about her medical expenses and missing more work in future. She also stated that she could lose her bladder and perhaps need chemotherapy for her cancerous tumors.
Rios alleged in her lawsuit that the manufacturer (Takeda Pharmaceuticals Ltd.) failed to adequately research their medication, and liable for not properly warning patients and doctors about the possible risk of developing bladder cancer with the long-term use of the medication.
Furthermore, A petition was filed in late august for consolidation of Actos bladder cancer lawsuits in a multidistrict litigation. According to a recent report, Plaintiffs Glen and Nina Weant, who filed the petition on August 31, requested to consolidate all Actos bladder cancer lawsuits in different federal courts before Judge G. Patrick Murphy for coordinated managing during pretrial litigation. However, the plaintiffs particularly requested to transfer all the federal Actos lawsuits to United Sates district court for the district of Illinois (southern).
The FDA approved Actos in July 1999. It is usually prescribed as an adjunct to diet and exercise in individuals with diabetes mellitus type 2. According to the patient medication guide, Actos usually works by reducing insulin resistance in user’s body, and helps by increasing insulin sensitivity in user’s cells.
Actos became the no. 1 diabetes pills in recent years. According to Associated Press, Actos took the number one position when a rival medication, Avandia (Rosiglitazone) banned in Europe and restricted in U.S. market due to its serious cardiovascular complications. However, a big sales drop this year as suspicion grows about the risk of developing bladder cancer with Actos.
Reportedly, market researchers now started to believe that this bladder cancer risk could spell the ending for a once very promising Type II diabetes medication.
Antibiotic Resistance - A Growing Threat For Humans
Antibiotics, the most important life saving drugs, may not show any effects in curing diseases if these resistance grows!
Actos Lawsuit -- Actos bladder cancer Litigation
Actos (Pioglitazone HCl) is the most widely prescribed medication by physicians for type II diabetes mellitus, which has been linked with an increased risk of congestive heart failure, liver damages, lactic acidosis, and recently with bladder cancer. More than 10 million people have already taken this drug, to improve their glycemic or blood sugar control. However, many of these people are now unfortunately exposed with the serious adverse effects of Actos. Among these people, some Actos users are now filing Actos lawsuit to seek compensation for their damages.
